Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

U.S. Food and Drug Administration Approved 30% More Drugs in 2012

Marketwired February 22, 2013

Free Research Reports on PAY, RPRX, RBCN and SFY Issued by the Bedford Report

Marketwired February 22, 2013

Repros Reports FDA Recommends Pivotal Study ZA-301 of Androxal(R) to be Completed as Originally Planned

Troy Schwensen February 21, 2013

Repros Therapeutics Corporate Update

Troy Schwensen February 11, 2013

Biotech Companies Attractive Targets for Pharma Companies Looking to Replace Lost Revenues

Marketwired January 30, 2013

The Real Story Behind RPRX, FURX, SMFG and MTU

Marketwired January 30, 2013

Free Research Report on Realty Income Corp., Repros Therapeutics, Inc., JoS. A. Bank Clothiers, Inc., PETsMART, Inc. and Hancock Holding Co.

PR Newswire January 30, 2013

Biotech M&A Activity to Rise in 2013 as Pharma Companies Look to Replace Lost Revenues

Marketwired January 29, 2013

Free Research Reports on AKS, HMSY, KERX and RPRX Issued by the Bedford Report

Marketwired January 29, 2013

Repros Updates Guidance for Top Line Results From First Pivotal Androxal(R) Study to Q3 2013

Troy Schwensen January 28, 2013

Repros Reports Core 1-Year DEXA Study Fully Enrolled Ahead of Schedule and Provides Update for Androxal(R) Clinical Program

Troy Schwensen January 7, 2013

Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids

Troy Schwensen January 3, 2013